Search
Zibrofusidic acid
go.drugbank.com/drugs/DB20799InvestigationalZibrofusidic acid has a monoisotopic molecular weight of 594.26 Da.
Evixapodlin
go.drugbank.com/drugs/DB21520InvestigationalEvixapodlin has a monoisotopic molecular weight of 690.22 Da.
Deutarserine
go.drugbank.com/drugs/DB19057InvestigationalDeutarserine is under investigation in clinical trial NCT04158687 (A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia).
Synonyms: D-serine-2-dCrisugabalin
go.drugbank.com/drugs/DB19300InvestigationalCrisugabalin is under investigation in clinical trial NCT06490484 (Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to
Afelimomab
go.drugbank.com/drugs/DB04956ExperimentalAfelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.
HPV-16 trojan peptide vaccine
go.drugbank.com/drugs/DB17496InvestigationalHPV-16 trojan peptide vaccine is an investigational cancer immunotherapy consisting of a novel Trojan peptide complex, composed of human papilloma virus 16 (HPV 16) epitopes, to stimulate antigen-specific
Mubodina
go.drugbank.com/drugs/DB17616ExperimentalMubodina is an investigational drug developed by Adienne Pharma & Biotech. It is a recombinant human minibody directed against complement component C5.
Tedisamil
go.drugbank.com/drugs/DB06200ExperimentalTedisamil (planned trade name Pulzium) is an investigational drug for atrial fibrillation and atrial flutter.
AM336
go.drugbank.com/drugs/DB06563ExperimentalLeconotide (development codes CNSB004 and AM336) is an omega-conotoxin peptide known for its analgesic properties, which work by blocking neuronal voltage-sensitive calcium channels.
Pretomanid
go.drugbank.com/drugs/DB05154ApprovedInvestigational[A182915] Pretomanid is an antimycobacterial agent that is administered with [Bedaquiline] and [Linezolid] to treat resistant forms of pulmonary TB.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates